Press Releases and Blog
Blog
ICYMI: Medicare “Delinking” Does Not Result In Savings, Increases Costs For Seniors And Taxpayers
As a so-called “delinking” measure continues to be discussed in Congress, specifically in the Medicare Part D program, it’s important lawmakers understand that this policy
Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
The House Ways and Means Committee will vote today on legislation that will include a so-called “delinking” policy in Medicare. Joe Grogan, visiting senior fellow
“Delinking” Proposal Increases Drug Costs For Medicare Beneficiaries And Taxpayers, Hands $10 Billion Giveaway To Big Pharma
The House Ways and Means Committee will vote tomorrow, May 8, on legislation that will include a so-called “delinking” policy in Medicare. To be clear,
ICYMI: RealClearHealth: JC Scott: Let’s Get Drug Pricing Legislation Right
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity Congress now has to get
Patient Access and Insulin: Market Forces, Innovative PBM Programs Lowering Costs for Patients
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies
Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO
Press Releases
PCMA Statement on Senate Judiciary Committee Hearing on Competition in The Prescription Drug Market
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of the U.S. Senate Committee on the Judiciary hearing, “Ensuring Affordable
PCMA Releases Statement on CMS Part D Biosimilar Substitution Announcement
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the recent announcement from the Centers for Medicare and Medicaid Services
PCMA Releases Statement on Kentucky House Bill 220
(Frankfort, KY) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the passage of House Bill 220 in Kentucky. “PCMA applauds the
PCMA Releases Statement On White House PBM Listening Session
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session
PCMA Urges HELP Committee Lawmakers To Reject False Blame Game, Hold Drug Companies Accountable For Anti-Competitive Practices
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of a U.S. Senate Committee on Health, Education, Labor, and Pensions
Waltz Health Joins Pharmaceutical Care Management Association
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Waltz Health is joining the trade association as its newest member. “PCMA is
ICYMI: Medicare “Delinking” Does Not Result In Savings, Increases Costs For Seniors And Taxpayers
As a so-called “delinking” measure continues to be discussed in Congress, specifically in the Medicare Part D program, it’s important lawmakers understand that this policy
Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
The House Ways and Means Committee will vote today on legislation that will include a so-called “delinking” policy in Medicare. Joe Grogan, visiting senior fellow
“Delinking” Proposal Increases Drug Costs For Medicare Beneficiaries And Taxpayers, Hands $10 Billion Giveaway To Big Pharma
The House Ways and Means Committee will vote tomorrow, May 8, on legislation that will include a so-called “delinking” policy in Medicare. To be clear,
ICYMI: RealClearHealth: JC Scott: Let’s Get Drug Pricing Legislation Right
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity Congress now has to get
Patient Access and Insulin: Market Forces, Innovative PBM Programs Lowering Costs for Patients
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies
Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO
Economists Ike Brannon and Anthony Lo Sasso: The Real Challenge Facing Independent Pharmacies
As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would
What They Are Saying: PBMs Help Businesses, Families, And Patients Save On Rx Costs, Allow Employers To Offer Competitive Benefits
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically
Pharmacy Benefit Companies Partner To Support Rural Pharmacies And Patients
This week, community pharmacists will conduct a “Fly-In” in Washington D.C. Undoubtedly, part of the message to Congress will be critical of pharmacy benefit companies,
RealClearMarkets Op-Ed: “Attacks On Pharmacy Benefit Managers Won’t Reduce Drug Prices”
As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of